口腔科

订阅

MedSci主页 / 所有栏目 / 口腔科

J Periodontal Res： 超支化核-多壳纳米载体作为口腔黏膜应用药物传递系统的研究

2018-03-31 MedSci MedSci原创

超支化核-多壳纳米载体粘膜疾病药物载体
关注

在口腔中，粘膜组织可能会有许多不同的病理状况，例如需要治疗的炎症性疾病（牙龈炎，牙周炎）和自身免疫性疾病（口腔扁平苔藓）。外用药物的应用是一种常见的治疗方法。但是它们的功效是有限的。唾液的稀释作用会阻碍药物制剂的粘附和渗透。因此，口服外用药物的生物利用度不足，患者可能长年遭受疾病。

在口腔中，粘膜组织可能会有许多不同的病理状况，例如需要治疗的炎症性疾病（牙龈炎，牙周炎）和自身免疫性疾病（口腔扁平苔藓）。外用药物的应用是一种常见的治疗方法。但是它们的功效是有限的。唾液的稀释作用会阻碍药物制剂的粘附和渗透。因此，口服外用药物的生物利用度不足，患者可能长年遭受疾病。

在本研究中，我们关于了核 - 多壳（CMS）纳米载体作为口腔粘膜组织的药物递送系统的潜在用途。为此，我们制备了猪咀嚼和颊粘膜并进行了Franz细胞扩散实验。使用共焦激光扫描显微镜分析荧光标记的CMS纳米载体渗入粘膜组织。在暴露于CMS纳米载体时，分别通过MTT和磺酰罗丹明B来测定牙龈上皮细胞的代谢和增殖活性。

结果显示载体渗透到粘膜组织中，而颗粒渗透到咀嚼粘膜更深处。电子顺磁共振波谱揭示载于CMS纳米载体上的3-羧基-2，2，5，5-四甲基-1-吡咯烷基氧基标记的糖皮质激素地塞米松从两种粘膜组织中的载体释放，但是在颊粘膜更多。与常规乳膏相比，两种情况下纳米载体的释放均优于传统乳膏。 CMS纳米载体在体外既不显示细胞毒性也不具有增殖作用。

结论：这些研究结果表明，CMS纳米载体可能是口服炎性疾病治疗中局部给药的新方法。

原始出处：

J. Jager， et al. 免疫性疾病（口腔扁平苔藓）。外用药物的应用是一种常见的治疗方法。但是它们的功效是有限的。唾液的稀释作用会阻碍药物制剂的粘附和渗透。因此，口服外用药物的生物利用度不足，患者可能长年遭受疾病。 在本研究中，我们关于了核 - 多壳（CMS）纳米载体作为口腔粘膜组织的药物递送系统的潜在用途。为此，我们制备了猪咀嚼和颊粘膜并进行了Franz细胞扩散实验。使用共焦激光扫描显微镜分析荧光标记的CMS纳米载体渗入粘膜组织。在暴露于CMS纳米载体时，分别通过MTT和磺酰罗丹明B来测定牙龈上皮细胞的代谢和增殖活性。 结果显示载体渗透到粘膜组织中，而颗粒渗透到咀嚼粘膜更深处。电子顺磁共振波谱揭示载于CMS纳米载体上的3-羧基-2，2，5，5-四甲基-1-吡咯烷基氧基标记的糖皮质激素地塞米松从两种粘膜组织中的载体释放，但是在颊粘膜更多。与常规乳膏相比，两种情况下纳米载体的释放均优于传统乳膏。 CMS纳米载体在体外既不显示细胞毒性也不具有增殖作用。 结论：这些研究结果表明，CMS纳米载体可能是口服炎性疾病治疗中局部给药的新方法。 原始出处： J. Jager， et al. Characterization of hyperbranched core‐multishell nanocarriers as an innovative drug delivery system for the application at the oral mucosa. Journal of Periodontal Research. 2018 February. doi：10.1111/jre.12487" target="_blank">Characterization of hyperbranched core‐multishell nanocarriers as an innovative drug delivery system for the application at the oral mucosa. Journal of Periodontal Research. 2018 February. doi：10.1111/jre.12487

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2032280, encodeId=741320322809d, content=<a href='/topic/show?id=08dd8e664ee' target=_blank style='color:#2F92EE;'>#药物传递#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87664, encryptionId=08dd8e664ee, topicName=药物传递)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Tue Feb 19 19:34:00 CST 2019, time=2019-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727206, encodeId=416f1e272063e, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Dec 23 08:34:00 CST 2018, time=2018-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645450, encodeId=b85e1645450e6, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Tue Jul 17 02:34:00 CST 2018, time=2018-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2075753, encodeId=da3c20e5753d6, content=<a href='/topic/show?id=2022e74603e' target=_blank style='color:#2F92EE;'>#纳米载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77460, encryptionId=2022e74603e, topicName=纳米载体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Thu Aug 02 11:34:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519995, encodeId=3b45151999520, content=<a href='/topic/show?id=6ab11032506f' target=_blank style='color:#2F92EE;'>#黏膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103250, encryptionId=6ab11032506f, topicName=黏膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=057f11309297, createdName=snowpeakxu, createdTime=Mon Apr 02 10:34:00 CST 2018, time=2018-04-02, status=1, ipAttribution=)]
    2019-02-19 ymljack

    #药物传递#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2032280, encodeId=741320322809d, content=<a href='/topic/show?id=08dd8e664ee' target=_blank style='color:#2F92EE;'>#药物传递#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87664, encryptionId=08dd8e664ee, topicName=药物传递)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Tue Feb 19 19:34:00 CST 2019, time=2019-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727206, encodeId=416f1e272063e, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Dec 23 08:34:00 CST 2018, time=2018-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645450, encodeId=b85e1645450e6, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Tue Jul 17 02:34:00 CST 2018, time=2018-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2075753, encodeId=da3c20e5753d6, content=<a href='/topic/show?id=2022e74603e' target=_blank style='color:#2F92EE;'>#纳米载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77460, encryptionId=2022e74603e, topicName=纳米载体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Thu Aug 02 11:34:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519995, encodeId=3b45151999520, content=<a href='/topic/show?id=6ab11032506f' target=_blank style='color:#2F92EE;'>#黏膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103250, encryptionId=6ab11032506f, topicName=黏膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=057f11309297, createdName=snowpeakxu, createdTime=Mon Apr 02 10:34:00 CST 2018, time=2018-04-02, status=1, ipAttribution=)]
    2018-12-23 feather89

    #PE#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2032280, encodeId=741320322809d, content=<a href='/topic/show?id=08dd8e664ee' target=_blank style='color:#2F92EE;'>#药物传递#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87664, encryptionId=08dd8e664ee, topicName=药物传递)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Tue Feb 19 19:34:00 CST 2019, time=2019-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727206, encodeId=416f1e272063e, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Dec 23 08:34:00 CST 2018, time=2018-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645450, encodeId=b85e1645450e6, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Tue Jul 17 02:34:00 CST 2018, time=2018-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2075753, encodeId=da3c20e5753d6, content=<a href='/topic/show?id=2022e74603e' target=_blank style='color:#2F92EE;'>#纳米载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77460, encryptionId=2022e74603e, topicName=纳米载体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Thu Aug 02 11:34:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519995, encodeId=3b45151999520, content=<a href='/topic/show?id=6ab11032506f' target=_blank style='color:#2F92EE;'>#黏膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103250, encryptionId=6ab11032506f, topicName=黏膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=057f11309297, createdName=snowpeakxu, createdTime=Mon Apr 02 10:34:00 CST 2018, time=2018-04-02, status=1, ipAttribution=)]
    2018-07-17 mei539

    #载体#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2032280, encodeId=741320322809d, content=<a href='/topic/show?id=08dd8e664ee' target=_blank style='color:#2F92EE;'>#药物传递#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87664, encryptionId=08dd8e664ee, topicName=药物传递)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Tue Feb 19 19:34:00 CST 2019, time=2019-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727206, encodeId=416f1e272063e, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Dec 23 08:34:00 CST 2018, time=2018-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645450, encodeId=b85e1645450e6, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Tue Jul 17 02:34:00 CST 2018, time=2018-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2075753, encodeId=da3c20e5753d6, content=<a href='/topic/show?id=2022e74603e' target=_blank style='color:#2F92EE;'>#纳米载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77460, encryptionId=2022e74603e, topicName=纳米载体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Thu Aug 02 11:34:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519995, encodeId=3b45151999520, content=<a href='/topic/show?id=6ab11032506f' target=_blank style='color:#2F92EE;'>#黏膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103250, encryptionId=6ab11032506f, topicName=黏膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=057f11309297, createdName=snowpeakxu, createdTime=Mon Apr 02 10:34:00 CST 2018, time=2018-04-02, status=1, ipAttribution=)]
    2018-08-02 apoenzyme

    #纳米载体#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2032280, encodeId=741320322809d, content=<a href='/topic/show?id=08dd8e664ee' target=_blank style='color:#2F92EE;'>#药物传递#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87664, encryptionId=08dd8e664ee, topicName=药物传递)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Tue Feb 19 19:34:00 CST 2019, time=2019-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727206, encodeId=416f1e272063e, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Dec 23 08:34:00 CST 2018, time=2018-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645450, encodeId=b85e1645450e6, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Tue Jul 17 02:34:00 CST 2018, time=2018-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2075753, encodeId=da3c20e5753d6, content=<a href='/topic/show?id=2022e74603e' target=_blank style='color:#2F92EE;'>#纳米载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77460, encryptionId=2022e74603e, topicName=纳米载体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Thu Aug 02 11:34:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519995, encodeId=3b45151999520, content=<a href='/topic/show?id=6ab11032506f' target=_blank style='color:#2F92EE;'>#黏膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103250, encryptionId=6ab11032506f, topicName=黏膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=057f11309297, createdName=snowpeakxu, createdTime=Mon Apr 02 10:34:00 CST 2018, time=2018-04-02, status=1, ipAttribution=)]
    2018-04-02 snowpeakxu

    #黏膜#

    0